6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advancing therapies for rare and inherited renal disorders. As more programs progress into mid- and late-stage development, the meeting provides a dedicated forum to address the scientific, clinical, and regulatory challenges shaping the next phase of kidney drug development.
The summit will unite experts from biopharma, academia, regulators, and patient advocacy organizations, working across indications such as IgAN, FSGS, ADPKD, Alport syndrome, C3G, and other rare renal conditions. With biologically complex diseases and heterogeneous patient populations, teams are increasingly challenged to design feasible trials, validate endpoints, and translate early signals into robust clinical evidence.
Across three days, the summit is designed to deliver practical, real-world insights that attendees can apply to their programs immediately. Sessions will explore approaches to regulatory alignment, biomarker and endpoint validation, and adaptive trial design in small patient populations. Drawing on case studies from late-stage programs and recent approvals, discussions will focus on making earlier, more confident development decisions while reducing downstream risk.
Confirmed speakers include KOLs from Boehringer Ingelheim, Novartis, Bayer, Takeda, Vertex Pharmaceuticals, CSL, Calliditas Therapeutics, Travere Therapeutics, Vera Therapeutics, Kidney Future, and others, offering perspectives from discovery through commercialization.
Key areas of focus include:
- Using biomarkers, surrogate endpoints, and advanced imaging to enable earlier proof-of-concept
- Improving trial feasibility and recruitment with external controls and adaptive designs
- Aligning clinical development with downstream value to maximize asset potential
- Applying next-generation disease models to improve clinical predictability and decision confidence
New for 2026, the summit introduces expanded content on adaptive platform trials, external control arms, and the use of natural history data to reduce patient burden, as well as interactive workshops focused on strengthening commercial strategy earlier in development.
Beyond the formal agenda, the meeting is designed to foster collaboration through interactive roundtables, speed networking, and small-group discussions, creating space for open dialogue among peers facing similar challenges.
The 6th Rare & Genetic Kidney Disease Drug Development Summit offers a focused, collaborative environment to benchmark strategies, share lessons learned, and accelerate the delivery of meaningful therapies to patients.
Find out more about the meeting: https://ter.li/mb8c64bp
